Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?

Slides:



Advertisements
Similar presentations
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma  André Veillette, Huaijian Guo  Critical Reviews.
Advertisements

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
The beauty of TLR agonists for CTCL
“Toll”-erance in the Skin
Figure 1 Radiation-induced effects on tumour cells
CD5: A New Partner for IL-6
CD271 on Melanoma Cell Is an IFN-γ-Inducible Immunosuppressive Factor that Mediates Downregulation of Melanoma Antigens  Junpei Furuta, Takashi Inozume,
Adrienne D. Cox, Kenneth P. Olive  Cancer Cell 
Cancer Immunotherapy by Dendritic Cells
Oncology Meets Immunology: The Cancer-Immunity Cycle
Figure 1 Immune mechanisms in liver homeostasis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Antigen-induced regulatory T cells
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
Microbial Symbiosis with the Innate Immune Defense System of the Skin
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3  Chiara Camisaschi, Annamaria De Filippo, Valeria.
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
Ana C. Anderson, Nicole Joller, Vijay K. Kuchroo  Immunity 
Imiquimod Inhibits Melanoma Development by Promoting pDC Cytotoxic Functions and Impeding Tumor Vascularization  Caroline Aspord, Laetitia Tramcourt,
Unraveling the Pros and Cons of Interferon-γ Gene Regulation
Figure 4 Macrophages in liver inflammation
Richard L. Gallo, Jamie J. Bernard 
Mesenchymal Stromal Cells: Facilitators of Successful Transplantation?
Mechanisms of immune escape in the tumor microenvironment.
Kavitha K. Reddy  Journal of Investigative Dermatology 
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Volume 27, Issue 2, Pages (August 2007)
Tilo Biedermann, Martin Röcken, José M. Carballido 
Johan Botling, MD, PhD, Martin Sandelin, MD, PhD 
Docosahexaenoic Acid Alleviates Atopic Dermatitis in Mice by Generating T Regulatory Cells and M2 Macrophages  Karyn A. Haitz, Niroshana Anandasabapathy 
Turning Tumors into Vaccines: Co-opting the Innate Immune System
Circulating Tumor Cells and Melanoma Progression
Yasmine Belkaid, Guillaume Oldenhove  Immunity 
Manipulated Microenvironment in Human Papilloma Virus–Infected Epithelial Cells: Is the CD40–CD154 Pathway Beneficial for Host or Virus?  Takatoshi Shimauchi,
Poly(I:C) Drives Type I IFN- and TGFβ-Mediated Inflammation and Dermal Fibrosis Simulating Altered Gene Expression in Systemic Sclerosis  Giuseppina A.
Michael P. O'Connell, Ashani T. Weeraratna 
Tumor-Associated Macrophages: From Mechanisms to Therapy
Immune responses induced by TLR TLR7/8 ligands in primary human DC subsets. Immune responses induced by TLR TLR7/8 ligands in primary human DC subsets.
How Low Cholesterol Is Good for Anti-viral Immunity
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Rhiannon M. Kelsh, Paula J. McKeown-Longo, Richard A.F. Clark 
Clinical Snippets Journal of Investigative Dermatology
Minutes of the Board of Directors Meeting
Jürgen C. Becker, David Schrama  Journal of Investigative Dermatology 
Nat. Rev. Urol. doi: /nrurol
Deciphering and Reversing Tumor Immune Suppression
Journal of Investigative Dermatology
Tobias R. Kollmann, Ofer Levy, Ruth R. Montgomery, Stanislas Goriely 
Rosacea: the Cytokine and Chemokine Network
Society for Investigative Dermatology 2010 Meeting Minutes
Journal of Investigative Dermatology
IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell Responsiveness to CpG DNA and Herpes Simplex Virus-1  Jurjen Tel, Ruurd Torensma, Carl G. Figdor, I.
David C. Soler, Thomas S. McCormick 
How Much Sun Protection Is Needed
David A. Martin, Jennifer E
Regulatory B Cells: Origin, Phenotype, and Function
TLR3: A Receptor that Recognizes Cell Injury Is Essential for Permeability Barrier Homeostasis Following UV Irradiation  Kenneth R. Feingold  Journal.
Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation
Stephen O'Neill, Jeremy Hughes  Kidney International 
Journal of Investigative Dermatology
Releasing the Brakes on Cancer Immunotherapy
Vaccines for Lung Cancer
Journal of Investigative Dermatology
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Influence of the tumor microenvironment on FL
Intratumoral CD4+ T Lymphodepletion Sensitizes Poorly Immunogenic Melanomas to Immunotherapy with an OX40 Agonist  Susumu Fujiwara, Hiroshi Nagai, Noriko.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Stable IL-10: A New Therapeutic that Promotes Tumor Immunity
Presentation transcript:

Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good? Jeremy Di Domizio, Olivier Demaria, Michel Gilliet  Journal of Investigative Dermatology  Volume 134, Issue 7, Pages 1797-1800 (July 2014) DOI: 10.1038/jid.2014.155 Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 pDCs in melanoma: turning bad into good. Melanoma drives pDC-mediated immunosuppression via three distinct mechanisms: (i) lack of activation, (ii) active suppression of type I IFN production, and (iii) alternate activation bypassing type I IFN production. Because of the lack of activation signals, tumor pDCs may retain an immature phenotype with high expression of ICOS ligand that costimulates T regulatory cells. Tumor cells also express BST2, and produce transforming growth factor-β and IL-10, which actively inhibit type I IFN induction in pDCs. Finally, melanoma cells can trigger LAG3-dependent alternate activation of pDC, leading to the production of IL-6 but not type I IFNs. pDC-derived IL-6 induces CCL2 production by monocytes, which initiates recruitment of myeloid-derived suppressor cells into the tumor microenvironment. Therapeutically, the presence of pDCs at the tumor site could be exploited to drive antitumor responses via their activation to produce type I IFNs using synthetic TLR7 and TLR9 agonists. Type I IFNs have the potential to unleash antitumor immunity by activating conventional DCs, T cells, and NK cells while inhibiting regulatory T cells. Furthermore, type I IFNs can induce cytotoxic activities of pDCs by inducing the expression of granzyme B and TRAIL, leading to local antitumor responses. The combined use of TLR agonists and neutralizing antibodies that fully restore the ability of pDCs to produce type I IFNs (anti-LAG-3, anti-IL-10, or anti-ILT7) should be considered for the generation of more effective antitumor responses. LAG-3, lymphocyte activation gene-3; mDC, myeloid dendritic cell; MDSC, myeloid-derived suppressor cell; MEL, melanoma; Mono, monocyte; NK, natural killer cell; pDC, plasmacytoid dendritic cell; TLR, Toll-like receptor; T reg, T regulatory cell. Journal of Investigative Dermatology 2014 134, 1797-1800DOI: (10.1038/jid.2014.155) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Journal of Investigative Dermatology 2014 134, 1797-1800DOI: (10 Journal of Investigative Dermatology 2014 134, 1797-1800DOI: (10.1038/jid.2014.155) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions